Interleukin 13 (Il-13) Acts As A Profibrotic Cytokine For  Recruitment Of Myofibroblasts In Oral Submucous Fibrosis

Mamatha G S  Reddy; Sachin C  Sarode; Rajiv S Desai

doi:10.48165/

Authors

Mamatha G S Reddy D.Y. Patil Vidyapeeth’s, Dr. D.Y. Patil Dental College and Hospital, Pimpri, Pune - 411 018, Maharashtra (India)
Sachin C Sarode D.Y. Patil Vidyapeeth’s, Dr. D.Y. Patil Dental College and Hospital, Pimpri, Pune - 411 018, Maharashtra (India)
Rajiv S Desai Nair Dental Hospital and College, Mumbai 400 008, Maharashtra (India)

DOI:

https://doi.org/10.48165/

Keywords:

Interleukin 13, myofibroblasts, oral submucous fibrosis, pathogenesis, transforming growth factor-β

Abstract

Oral submucous fibrosis (OSF) is a chronic inflammatory condition due to areca nut (Areca catechu) chewing which induces fibrosis leading to the difficulty in mouth opening. Various profibrotic cytokines and chemokines have been found involved in fibrosis. The present study was aimed to find the role of interleukin 13 (IL-13) in recruiting the myofibroblasts and as a causative factor for fibrosis in OSF. Twenty-five sections of OSF tissue and ten sections of normal mucosa were stained with IL-13, TGF-β1 and α-SMA antibodies using immunohistochemical method. Immunostaining was done to assess staining intensity and percentage of positive cells. The results were analyzed by SPSS software. The expression of all three markers IL-13, TGF β1 and α-SMA showed significant difference between control and OSF (p < 0.001), control and early OSF (p < 0.001) control and advanced OSF (p < 0.001). No statistical difference was found between early OSF and advanced OSF. Significant expression of IL-13 and its correlation with TGF-β and α SMA suggests its role in pathogenesis of OSF.

Downloads

Download data is not yet available.

References

Aliprantis, A.O., Wang, J., Fathman, J.W., Lemaire, R., Dorfman, D.M. and Lafyatis, R. 2007. Transcription factor TGF-beta regulates skin sclerosis through its function in innate immunity and via IL-13. Proceedings of National Academic Sciences, 104(8): 2827-2830.

Mamatha G.S. Reddy et al.

Angadi, P.V., Kale, A.D. and Hallikerimath, S. 2011. Evaluation of myofibroblasts in oral submucous fibrosis: Correlation with disease severity. Journal of Oral Pathology and Medicine, 40: 208- 213.

Blease, K., Jakubzick, C., Westwick, J., Lukacs, N., Kunkel, S.L. and Hogaboam, C.M. 2001. Therapeutic effect of IL-13 immunoneutralization during chronic experimental fungal asthma. The Journal of Immunology, 166(8): 5219-5224.

Chang, Y.C., Tsai, C.H., Lai, Y.L., Yu, C.C., Chi, W.Y., Li, J.J. and Chang, W.W. 2014. Arecoline‐ induced myofibroblast trans-differentiation from human buccal mucosal fibroblasts is mediated by ZEB 1. Journal of Cellular and Molecular Medicine, 18: 698-708.

Chiaramonte, M.G., Donaldson, D.D., Cheever, A.W. and Wynn, T.A. 1999. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. The Journal of Clinical Investigation, 104: 777-785.

Clive, R.T., Shang Rong, S., Nancy, J.B. and Nancy, W. 2006. Techniques of immunohistochemistry: Principles, pitfalls and standardization. pp.7-8. In: Diagnostic Immunohistochemistry (ed. J.D. David), Elsevier, Philadelphia, USA.

Fuschiotti, P., Larregina, A.T., Ho, J., Feghali‐Bostwick, C. and Medsger Jr, T.A., 2013. Interleukin‐ 13-producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis. Arthritis and Rheumatism, 65: 236-246.

Gandhi, P. and Prasad, U.C. 2017. Evaluation of myofibroblasts in oral submucous fibrosis and oral squamous cell carcinoma: The pathogenesis and correlation. Dental Research Journal, 14(5): 314-317.

Guo, J., Yao, H., Lin, X., Xu, H., Dean, D., Zhu, Z., Liu, G. and Sime, P. 2015. IL-13 induces YY1 through the AKT pathway in lung fibroblasts. PLoS One, 10(3), p.e0119039. Hashimoto, S., Gon, Y., Takeshita, I., Maruoka, S. and Horie, T. 2001. IL-4 and IL-13 induce myofibroblastic phenotype of human lung fibroblasts through c-Jun NH2-terminal kinase– dependent pathway. Journal of Allergy and Clinical Immunology, 107: 1001-1008. Kale, A.D., Mane, D.R. and Shukla, D. 2013. Expression of transforming growth factor β and its correlation with lipodystrophy in oral submucous fibrosis: An immunohistochemical study. Medicina Oral Patologia Oral y Cirugia Bucal, 18(1): p.e12.

Kamath, V.V., Krishnamurthy, S., Satelur, K.P. and Rajkumar, K. 2015. Transforming growth factor β1 and TGF-β2 act synergistically in the fibrotic pathway in oral submucous fibrosis: An immunohistochemical observation. Indian Journal of Medical and Pediatric Oncology, 36(2): 111-114.

Kaviratne, M., Hesse, M., Leusink, M., Cheever, A.W., Davies, S.J., McKerrow, J.H., Wakefield, L.M., Letterio, J.J. and Wynn, T.A. 2004. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-β independent. The Journal of Immunology, 173(6): 4020-4029.

Keane, M.P., Gomperts, B.N., Weigt, S., Xue, Y.Y., Burdick, M.D., Nakamura, H., Zisman, D.A., Ardehali, A., Saggar, R., Lynch, J.P. and Hogaboam, C. 2007. IL-13 is pivotal in the fibro obliterative process of bronchiolitis obliterans syndrome. The Journal of Immunology, 178: 511- 519.

Kolodsick, J.E., Toews, G.B., Jakubzick, C., Hogaboam, C., Moore, T.A., McKenzie, A., Wilke, C.A., Chrisman, C.J. and Moore, B.B. 2004. Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts. The Journal of Immunology, 172: 4068-4076.

Lee, C.G., Homer, R.J., Zhu, Z., Lanone, S., Wang, X., Koteliansky, V., Shipley, J.M., Gotwals, P., Noble, P., Chen, Q. and Senior, R.M. 2001. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor β1. Journal of Experimental Medicine, 194: 809-822.

Mirza, D. And Amanat, N. 2014. Expression of integrin ανβ6 (alphavbeta6) in oral submucous fibrosis: A potentially malignant condition of oral cavity. Pakistan Oral and Dental Journal, 34(1): 66-73.

Interleukin-13 - A profibrotic cytokine for myofibroblasts in OSF 227

Moutasim, K.A., Jenei, V., Sapienza, K., Marsh, D., Weinreb, P.H., Violette, S.M., Lewis, M.P., Marshall, J.F., Fortune, F., Tilakaratne, W.M. and Hart, I.R. 2011. Betel‐derived alkaloid up‐ regulates keratinocyte alphavbeta6 integrin expression and promotes oral submucous fibrosis. The Journal of Pathology, 223(3): 366-377.

Philip, T., Kumar, T.D., Rajkumar, K., Karthik, K.R., Priyadharsini, N. and Kumar, A.R. 2014. Immunohistochemical evaluation of myofibroblasts using alpha-smooth muscle actin in oral submucous fibrosis. SRM Journal of Research in Dental Sciences, 5(4): 243-244.

Rael, E.L. and Lockey, R.F. 2011. Interleukin-13 signaling and its role in asthma. World Allergy Organization Journal, 4(3): 54-57.

Raganathan, K. and Gauri, M. 2006. An overview of classification schemes for oral submucous fibrosis. Journal of Oral and Maxillofacial Pathology, 10(2): 55-58.

Rajalalitha, P. and Vali, S. 2005. Molecular pathogenesis of oral submucous fibrosis – A collagen metabolic disorder. Journal of Oral Pathology and Medicine, 34(6): 321-328. Rao, B., Malathi, N., Narashiman, S. and Rajan, S.T. 2014. Evaluation of myofibroblasts by expression of alpha smooth muscle actin: A marker in fibrosis, dysplasia and carcinoma. Journal of Clinical and Diagnostic Research, 8(4): p. ZC14.

Saito, A., Okazaki, H., Sugawara, I., Yamamoto, K. and Takizawa, H. 2003. Potential action of IL-4 and IL-13 as fibrogenic factors on lung fibroblasts in vitro. International Archives of Allergy and Immunology, 132: 168-176.

Sarode, G., Sarode, S.C., Deshmukh, R., Raktade, P. and Patil, S. 2017. Myofibroblasts could be recruited in a chemokine (C‐C motif) ligand 2‐dependent manner in pathogenesis of oral submucous fibrosis. Journal of Oral Pathology & Medicine, 46: 443-447.

Saw, V.P., Offiah, I., Dart, R.J., Galatowicz, G., Dart, J.K., Daniels, J.T. and Calder, V.L. 2009. Conjunctival interleukin-13 expression in mucous membrane pemphigoid and functional effects of interleukin-13 on conjunctival fibroblasts in vitro. The American Journal of Pathology, 175(6): 2406-2415.

Singh, N., Kaur, G. and Kaur, J. 2017. Assessment of expression of myofibroblast in oral submucous fibrosis. International Journal of Medical Research Professionals, 3(2): 239-241. Soini, Y., Puhakka, A., Kahlos, K., Säily, M., Pääkkö, P., Koistinen, P. and Kinnula, V. 2001. Endothelial nitric oxide synthase is strongly expressed in malignant mesothelioma but does not associate with vascular density or the expression of VEGF, FLK1 or FLT1. Histopathology, 39: 179-186.

Sudarshan, R., Annigeri, R.G. and Vijayabala, S.G. 2012. Pathogenesis of oral submucous fibrosis: The past and current concepts. International Journal of Oral and Maxillofacial Pathology, 3(2): 27-36.

Wynn, T.A. and Ramalingam, T.R. 2012. Mechanisms of fibrosis: Therapeutic translation for fibrotic disease. Nature Medicine, 18(7): 1028-1032.

Wynn, T.A. 2008. Cellular and molecular mechanisms of fibrosis. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland, 214: 199-210.